Bayesian statistics in oncology: A guide for the clinical investigator

Cancer

Volumn 115, Issue 23, 2009, Pages 5371-5381

  Adamina, Michel ^a,b   Tomlinson, George ^c   Guller, Ulrich ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bayesian analysis; Biostatistics; Clinical trial; Oncology

Indexed keywords

BAYES THEOREM; CANCER STATISTICS; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; PRIORITY JOURNAL; PROBABILITY; REVIEW; STATISTICAL ANALYSIS;

BAYES THEOREM; BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; FORECASTING; MEDICAL ONCOLOGY; PROBABILITY; RANDOM ALLOCATION;

EID: 72249115118     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24628     Document Type: Review

References (51)

1. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792. (Pubitemid 41549890)
2. Falcone A, Antonuzzo A, Danesi R, et al. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer. 1999;86: 470-476. (Pubitemid 29347409)
3. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755-2763.
4. Berry DA. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin Trials. 2005;2:295-300.
5. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in nonsmall- cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet. 1997;350:161-165.
6. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123-136. (Pubitemid 27345199)
7. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999;52:137-148.
8. Bayes T. An essay towards solving a problem in the doctrine of chances. Philos Trans R Soc Lond. 1763;53:370-418.
9. Feinberg SE. When did Bayesian inference become "Bayesian." Bayesian Anal. 2006;1:1-40.
10. Katzman S, Kern AD, Bejerano G, et al. Human genome ultraconserved elements are ultraselected. Science. 2007;317:915. (Pubitemid 47301312)
11. Cooper NJ, Sutton AJ, Abrams KR, Turner D, Wailoo A. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ. 2004;13:203-226. (Pubitemid 38292479)
12. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. Int J Technol Assess Health Care. 2001;17:69-82.
13. Kording K. Decision theory: what "should" the nervous system do? Science. 2007;318:606-610.
14. Ashby D, Smith AF. Evidence-based medicine as Bayesian decision-making. Stat Med. 2000;19:3291-3305.
15. Lobell DB, Burke MB, Tebaldi C, Mastrandrea MD, Falcon WP, Naylor RL. Prioritizing climate change adaptation needs for food security in 2030. Science. 2008;319:607-610. (Pubitemid 351197060)
16. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999;130:995-1004.
17. Parmar MK, Griffiths GO, Spiegelhalter DJ, Souhami RL, Altman DG, van der SE. Monitoring of large randomised clinical trials: a new approach with Bayesian methods. Lancet. 2001;358:375-381.
18. Louis TA. Introduction to Bayesian methods II: fundamental concepts. Clin Trials. 2005;2:291-294. (Pubitemid 41306269)
19. Spiegelhalter DJ, Abrams KR, Myles JP.Bayesian Approaches to Clinical Trials and Health Care Evaluation. 1st ed. New York, NY: John Wiley & Sons: 2004.
20. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23: 3105-3124. (Pubitemid 39334902)
21. Chaloner K, Rhame FS. Quantifying and documenting prior beliefs in clinical trials. Stat Med. 2001;20:581-600. (Pubitemid 32166421)
22. Parmar MK, Spiegelhalter DJ, Freedman LS. The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee. Stat Med. 1994;13:1297-1312.
23. Kadane JB. Prime time for Bayes. Control Clin Trials. 1995;16:313-318.
24. Guller U, Delong ER. Interpreting statistics in medical literature: a vade mecum for surgeons. J Am Coll Surg. 2004; 198:441-458. (Pubitemid 38283736)
25. Goodman SN. Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials. 2005;2:282-290. (Pubitemid 41306268)
26. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-3685. (Pubitemid 46252462)
27. Giles FJ, Kantarjian HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003;21:1722-1727.
28. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326:472.
29. van der Tweel I, van Noord PA. Early stopping in clinical trials and epidemiologic studies for "futility": conditional power versus sequential analysis. J Clin Epidemiol. 2003;56: 610-617.
30. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics. 2007;63:429-436. (Pubitemid 47222559)
31. Muler JH, McGinn CJ, Normolle D, et al. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol. 2004; 22:238-243. (Pubitemid 41095087)
32. Normolle D, Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol. 2006;24: 4426-4433. (Pubitemid 46630980)
33. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002;58: 823-831. (Pubitemid 36133760)
34. Jennison C, Turnbull BW. Meta-analyses and adaptive group sequential designs in the clinical development process. J Biopharm Stat. 2005;15:537-558. (Pubitemid 40967298)
35. Mercier C, Ciccolini J, Pourroy B, et al. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit. 2006;28:212-218. (Pubitemid 44314951)
36. Fan XF, DeMets DL, Lan KK. Conditional bias of point estimates following a group sequential test. J Biopharm Stat. 2004;14:505-530. (Pubitemid 38715797)
37. Goodman SN. Stopping at nothing? Some dilemmas of data monitoring in clinical trials. Ann Intern Med. 2007;146:882-887.
38. Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int J Epidemiol. 2006;35:765-775.
39. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med. 2008;27:625-650.
40. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539-546.
41. Moye LA. Bayesians in clinical trials: asleep at the switch. Stat Med. 2008;27:469-482.
42. Spiegelhalter DJ, Abrams KR, Myles JP. Sensitivity Analysis and "Robust" Priors. Bayesian Approaches to Clinical Trials and Health Care Evaluation. 1st ed. New York, NY: John Wiley & Sons; 2004:165-167.
43. Spiegelhalter DJ, Freedman LS, Parmar MK. Bayesian approaches to randomized trials. J R Stat Soc Ser A. 2008; 157:357-416.
44. WinBugs, jointly developed by the MRC Biostatistics Unit and the Imperial College School of Medicine at St Mary's, London, UK. Available at: http://www.mrc-bsu.cam.ac.uk/ bugs/winbugs/contents.shtml Accessed April 24, 2008.
45. OpenBugs, the University of Helsinki, Finland. Available at: http://mathstat.helsinki.fi/openbugs/ Accessed April 24, 2008.
46. Congdon P. Bayesian Statistical Modelling. 2nd ed. New York, NY: John Wiley & Sons; 2007.
47. Congdon P. Applied Bayesian Modelling. 1st ed. New York, NY: John Wiley & Sons; 2003.
48. R Development Core Team. R: A Language and Environment for Statistical Computing. Version 2.8. 1st ed. Vienna, Austria: R Corporation; 2008.
49. Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol. 2005;58:261-268. (Pubitemid 40249468)
50. Austin PC, Brunner LJ, Hux JE. Bayeswatch: an overview of Bayesian statistics. J Eval Clin Pract. 2002;8:277-286.
51. The BaSiS Group. BaSiS: Bayesian Standards in Science. Standards for Reporting of Bayesian Analyses in the Scientific Literature. Available at: http://lib.stat.cmu.edu/bayes workshop/2001/BaSis.html Accessed April 24, 2008.